Table 2. Inflammatory/anti-inflammatory properties of monocytes and carotid plaque of nondiabetic and diabetic patients.

	Non-diabetic patients	Diabetic patients	P-value*
n	12	12	-
mRNA level in monocytes
TNF-α	1.0 [0.8–1.7]	1.7 [1.0–5.6]	0.049
IL-6	1.0 [0.6–1.7]	0.7 [0.3–1.5]	0.525
IL-10	1.0 [0.3–1.4]	0.4 [0.2–0.9]	0.025
CD14	1.0 [0.7–1.4]	1.5 [1.1–1.8]	0.078
CD16	1.0 [0.8–1.4]	0.8 [0.7–1.5]	0.862
CD68	1.0 [0.8–1.1]	0.9 [0.8–0.9]	0.166
mRNA level in plaque
TNF-α	1.0 [0.7–2.0]	1.7 [1.1–3.3]	0.042
IL-6	1.0 [0.5–1.1]	1.8 [1.0–4.1]	0.038
IL-10	1.0 [0.5–1.4]	1.4 [0.9–2.0]	0.149
MHC-II	1.0 [0.5–1.6]	0.9 [0.3–1.9]	0.603
CD86	1.0 [0.8–1.8]	1.0 [0.6–1.6]	0.908
CD206	1.0 [0.6–1.4]	0.8 [0.4–2.1]	0.644
Dectin-1	1.0 [0.4–2.1]	1.8 [0.5–6.4]	0.326
Percent of positive cells in plaque
TNF-α (%)	54.2 [44.8–63.9]	65.5 [52.1–76.1]	0.193
IL-6 (%)	42.9 [38.7–54.9]	63.2 [40.8–71.1]	0.040
IL-10 (%)	70.9 [59.3–83.7]	58.0 [37.6–65.2]	0.019
MHC-II (%)	75.4 [66.4–78.8]	83.1 [73.7–88.1]	0.094
CD86 (%)	14.7 [11.9–23.5]	17.5 [11.4–22.7]	0.729
CD206 (%)	32.2 [25.5–42.5]	37.4 [26.6–40.4]	0.817
CD3 (%)	10.3 [8.6–14.0]	13.0 [8.9–15.0]	0.299

Data are shown as the median [IQR]. The mRNA expression levels of nondiabetic patients are set at 1.0 and relative values are shown.

^*nondiabetic versus diabetic patients